multiple myeloma, EU and CHMP
News Medical on MSN2d
Interactive atlas unveils immune changes in multiple myelomaMultiple Myeloma (MM) is an incurable blood cancer, leading to weakened immunity, bone damage, and other serious health ...
The department used its new system for determining whether a condition is service-connected to give affected veterans access ...
GSK has announced positive headline interim analysis outcomes from a Phase III trial, which is evaluating Blenrep (belantamab ...
Patient dosing has begun in a phase 1 trial evaluating QXL138AM, a masked immunocytokine targeting CD138, in advanced solid ...
Our additional preliminary studies demonstrate that dual targeting of multiple myeloma cells and BM-CAFs by CAR-T cells is ...
GSK is carving out a niche for Blenrep in the second-line multiple myeloma setting, for which it projects multi-blockbuster ...
During a Case-Based Roundtable® event, Saad Z. Usmani, MD, FACP, MBA, discussed quality of life and the future with CAR ...
Growing from a small community led initiative to a major fundraiser, the The Walk of Champions began with a modest $12,000 ...
Multiple myeloma is the second most common hematologic malignancy, but there is a treatment gap for patients with disease ...
Multiple myeloma (MM) is an incurable blood cancer, leading to weakened immunity, bone damage, and other serious health ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback